News in Brief
Sudden hearing loss study reaches milestone: AudioCure Pharma enrolls more than half of the patients in AC102 study
A single application of the novel compound AC102 almost completely restores noise-induced hearing loss in preclinical models. This is the key finding of a recent publication in the prestigious scientific journal PNAS by the Berlin-based start-up AudioCure Pharma.
Sudden Hearing Loss: AudioCure’s Novel Compound AC102 Restores Hearing in Preclinical Models, Published in PNAS
A single application of the novel compound AC102 almost completely restores noise-induced hearing loss in preclinical models. This is the key finding of a recent publication in the prestigious scientific journal PNAS by the Berlin-based start-up AudioCure Pharma.
Sudden Hearing Loss: Recent Clinical Trial HODOKORT Questions Benefits of Glucocorticoid Treatment
High-dose glucocorticoids are no more effective than the standard-dose in treating patients with sudden hearing loss. Moreover, they are associated with more side effects and significantly worse outcomes for speech recognition and tinnitus perception. Additionally, 60% of patients treated with the standard dose had not fully recovered by the end of the study.
AudioCure Pharma GmbH to present preclinical and clinical data on its lead candidate AC102 at ARO 2024 MidWinter Meeting in Anaheim (CA) on February 03-7 2024
AC102-201: A Phase 2 Clinical Trial Comparing the Efficacy of AC102, an Innovative Small Molecule, to Corticosteroids in Patients with Idiopathic Sudden Sensorineural Hearing Loss Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma GmbH, will present the AC102-201...
AudioCure Pharma Receives Hearing Technology Innovator Award for its Innovative Compound AC102 for the Treatment of Sudden Hearing Loss
AudioCure is pleased to announce that it has been awarded for their innovative therapeutic small molecule, AC102, by the Hearing Technology Innovator Awards™, honoring technological innovation and accomplishments in the hearing industry.
Offene Veranstaltung: „Stand der Forschung und der aktuellen klinischen Studie“
AudioCure Pharma GmbH to attend upcoming ENT Congresses in Budweis (CZ)
České Budějovice, 31st May – 2nd June 2023: 84. Kongres České́ společnosti Otorinolaryngologie a chirurgie hlavy a krku ČLS JEP The Czech Society of Otorhinolaryngology and Head and Neck Surgery establishes recommended practices in the field and ensures...
AudioCure Pharma GmbH to attend upcoming ENT Congress in Leipzig (DE)
Leipzig, 18-20th May 2023 - 94. Jahresversammlung der DGHNO-KHC, Congress Center Leipzig The German Society of Oto-Rhino-Laryngology, Head and Neck Surgery is dedicated to the advancement of scientific and clinical knowledge in its fields. AudioCure CEO, Reimar...
AudioCure Pharma GmbH to present preclinical and clinical data on its lead candidate AC102 at ARO 2023 MidWinter Meeting in Orlando (FL) on February 11-15 2023
Dr. Michael Nieratschker from Allgemeines Krankenhaus Medical University of Vienna, Austria will present preclinical results about the effect of AC102 in a model of electrode insertion trauma at the ARO 2023 in Orlando. Moreover, Dr Reimar Schlingensiepen, CEO of AudioCure Pharma GmbH, will talk about the results of a Phase I clinical trial with AC102 in healthy volunteers.
AudioCure Pharma initiates Phase 2 clinical trial of lead molecule AC102 for the treatment of hearing loss
AudioCure Pharma GmbH, a pharmaceutical company based in Berlin, Germany, announced today that the first healthy volunteers have been included into the Phase I trial with the first-in-class molecule AC102. Main primary endpoints of the open-label study are safety and tolerability of AC102-suspension after injection into the middle ear.